Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
2.5 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing Cancer Survival Rate
4.2.2 Growing Demand for Advanced Therapies
4.2.3 Less Number of Side Effects as Compared to Conventional Treatment Methods
4.2.4 Growth of Cancer Healthcare Facilities in Emerging Countries
4.2.5 Changing Lifestyle and Increasing Smoking Population in Middle East & Africa
4.3 Restraints
4.3.1 High cost of Cancer Biological Therapy
4.4 Opportunities
4.4.1 UnTapped Types of Cancers
5 Market Factor Analysis
5.1 Porter's Five Forces Model
5.1.1 Bargaining power of suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
6 Global Cancer Biological Therapy Market, by phases
6.1 Introduction
6.2 Phases
7 Global Cancer Biological Therapy Market, by Application
7.1 Introduction
7.2 Monoclonal Antibodies
7.3 Interferons
7.4 Interleukins
7.5 Cancer growth inhibitors
7.6 Gene Therapy
7.7 Colony-Stimulating Factors
8 Global Cancer Biological Therapy Market, by End Users
8.1 Introduction
8.2 Hospitals & Clinics
8.3 Cancer Research Centers
8.4 Laboratories
9 Global Cancer Biological Therapy Market, by Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 UK
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Republic of Korea
9.4.5 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
12 Competitive Landscape
12.1 Company Share Analysis
13 Company Profiles
13.1 Amgen Inc.
13.1.1 Company Overview
13.1.2 Product/Business Overview
13.1.3 Adherium Health: Financials
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.2 Bristol-Myers Squibb
13.2.1 Company Overview
13.2.2 Product overview
13.2.3 Financial Overview
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.3 Celgene Corporation
13.3.1 Company Overview
13.3.2 Product Overview
13.3.3 Financial Overview
13.3.4 Key Development
13.3.5 SWOT Analysis
13.4 ELI Lilly and Company
13.4.1 Company Overview
13.4.2 Product Overview
13.4.3 Financial Overview
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.5 EnGeneIC Ltd
13.5.1 Company Overview
13.5.2 Product overview
13.5.3 Financial Overview
13.5.4 Key Developments
13.5.5 SWOT Analysis